Using SGLT2 inhibitors to treat acute kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients diagnosed with acute kidney disease (AKD). Researchers aim to determine if these medications can reduce protein levels in urine and improve kidney health during the critical period following an acute kidney injury. The study will be randomized and placebo-controlled, involving multiple centers in Taiwan, and will include various SGLT2 inhibitors such as dapagliflozin, empagliflozin, and canagliflozin. The goal is to provide a potential treatment option for patients who currently have limited options for improving outcomes in AKD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years and \< 80 years
* Diagnosed with acute kidney disease
* Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73m²
* Albuminuria \> 100 mg/g or proteinuria \> 300 mg/g (adjusted by urine creatinine)
* Diagnosed with diabetes or chronic kidney disease

Exclusion Criteria:

* Received sodium-glucose cotransporter 2 (SGLT2) inhibitors within 28 days prior to enrollment
* Patients with type 1 diabetes
* Receiving aggressive immunosuppressive therapy for glomerulonephritis
* Obstructive nephropathy
* Polycystic kidney disease
* Malignancy within 3 months or expected to undergo aggressive treatment such as chemotherapy, radiation therapy, immunotherapy, or targeted therapy in the future
* Pregnant or breastfeeding women
* Clinically assessed as not having recovered from acute kidney injury
* Clinically assessed as at high risk for complications related to SGLT2 inhibitors

Where it's running

• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Study coordinator: Szu-Yu Pan, MD, PhD
• Email: szuyupan@ntu.edu.tw
• Phone: +886-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Restarting RAS inhibitors after AKI: a quick test in hospitalized adults

  This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT07734636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.